Skip to Content
Søk Menu

EADV20: Optimizing outcomes in moderate-to-severe atopic dermatitis

Få tilgang

Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.

Relatert innhold

Atopisk dermatitt: «Fra molekylære signaler til målrettede behandlinger»

/ Almirall
Atopisk dermatitt
Giovanni Damiani

A lot of Factors Increase the Comorbidity at Atopic Dermatitis

/ Giovanni Damiani
Atopisk dermatittEADV24 Play the Video 2:19
Sascha D. W. Stave

Safety Is One of the Main Drivers for Atopic Dermatitis Patient Preferences of Treatment

/ Sascha D. W. Stave
Atopisk dermatittEADV24 Play the Video 07:39
Thrasyvoulos Tzellos

AD: Promising Long-Term Safety Profile for Dupilumab in Real-World Data

/ Thrasyvoulos Tzellos
Atopisk dermatittEADV24 Play the Video 02:51

LBA: Lebrikizumab Provides Long-Term Efficacy and Safety in Atopic Dermatitis with a Well-Tolerated Safety Profile

/ Jan Andreasen
Atopisk dermatittEADV24
Anna Sophie Nicolo Belling Krontoft

Conversation Cards for Patients with Atopic Dermatitis

/ Anna Sophie Belling Krontoft
Atopisk dermatittEADV24 Play the Video 2:56
April Armstrong

Exciting Data on Atopic Dermatitis from EADV 2024

/ April Armstrong
Atopisk dermatittEADV24 Play the Video 04:14
Ida Vittrup

Risk Factors for JAK-Inhibitor Treatment in Atopic Dermatitis

/ Ida Vittrup
Atopisk dermatittEADV23 Play the Video 03:46
Stephan Weidinger

New Treatments for Atopic Dermatitis to Come

/ Stephan Weidinger
Atopisk dermatittEADV23 Play the Video 2:57
Back to top